Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice

Atherosclerosis

Volumn 227, Issue 1, 2013, Pages 58-64

  Handattu, Shaila P ^a   Nayyar, Gaurav ^a   Garber, David W ^a   Palgunachari, Mayakonda N ^a   Monroe, Candyce E ^a   Keenum, Tamara D ^a   Mishra, Vinod K ^a   Datta, Geeta ^a   Anantharamaiah, G M ^a  

^a and Clinical Center   (United States)

Author keywords

Atherosclerosis; Cholesterol; Inflammation; Oxidation; Peptides

Indexed keywords

AC HE18A NH2 PROTEIN; APOLIPOPROTEIN E; CARDIOVASCULAR AGENT; CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MR18L PROTEIN; PEPTIDE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CELL STRAIN HEPG2; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIETARY INTAKE; FEMALE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHOLESTEROL; FEMALE; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIPOPROTEINS; MACROPHAGES; MICE; PEPTIDE FRAGMENTS; PEPTIDES; REACTIVE OXYGEN SPECIES; RECEPTORS, LDL;

EID: 84873458334     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.10.064     Document Type: Article

References (20)

1. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
2. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1307.
3. National Cholesterol Education Program Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994, 89:1333-1445.
4. Bradley W.A., Hwang S.L., Karlin J.B., et al. Low-density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low density lipoproteins. J Biol Chem 1984, 259:14728-14735.
5. Gianturco S.H., Gotto A.M., Huang S.L.C., et al. Apolipoprotein E mediates uptake of Sf 100-400 hypertriglyceridemic very low density lipoproteins by the low density lipoprotein receptor pathway in normal human fibroblasts. J Biol Chem 1983, 258:4526-4533.
6. Davignon J. Apolipoprotein E and atherosclerosis: beyond liver effect. Arterioscler Thromb Vasc Biol 2005, 25:267-269.
7. Zaiou M., Arnold K.S., Newhouse Y.M., et al. Apolipoprotein E-low density lipoprotein receptor interaction: influences of basic residue and amphipathic α-helix organization in the ligand. J Lipid Res 2000, 41:1087-1095.
8. Datta G., Chaddha M., Garber D.W., et al. The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry 2000, 39:213-220.
9. Garber D.W., Handattu S., Aslan I., Datta G., Chaddha M., Anantharamaiah G.M. Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice. Atherosclerosis 2003, 168:2229-2237.
10. Gupta H., White C.R., Handattu S., et al. Apolipoprotein E mimetic peptide dramatically lowers plasma cholesterol and restores endothelial function in watanabe heritable hyperlipidemic rabbits. Circulation 2005, 111:3112-3118.
11. Datta G., White C.R., Dashti N., et al. Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH(2). Atherosclerosis 2010, 208:134-141.
12. Nayyar G., Handattu S.P., Monroe C.E., et al. Two adjacent domains (141-150 and 151-160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effects. Atherosclerosis 2010, 208:449-457.
13. Nayyar G, Garber DW, Palgunachari MN, et al. Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice. Atherosclerosis . http://dx.doi.org/10.1016/j.atherosclerosis.2012.05.040.
14. Handattu S.P., Datta G., Epand R.M., et al. Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice. J Lipid Res 2010, 51:3491-3499.
15. Segrest J.P., De Loof H., Dohlman J.G., Brouillette C.G., Anantharamaiah G.M. Amphipathic helix motif: classes and properties. Proteins 1990, 8:103-117.
16. Palgunachari M.N., Mishra V.K., Lund-Katz S., et al. Only the two end helixes of eight tandem amphipathic helical domains of human apo A-I have significant lipid affinity: implications for HDL assembly. Arterioscler Thromb Vasc Biol 1996, 16:328-338.
17. Garber D.W., Kulkarni K.R., Anantharamaiah G.M. A sensitive and convenient method for lipoprotein profile analysis of individual mouse plasma samples. J Lipid Res 2000, 41:1020-1026.
18. Nayyar G., Mishra V.K., Handattu S.P., et al. Sidedness of interfacial arginine residues and anti-atherogenicity of apolipoprotein A-I mimetic peptides. J Lipid Res 2012, 53:849-858.
19. Garber D.W., Datta G., Chaddha M., et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res 2001, 42:545-552.
20. Mahley R.W., Ji Z.S. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 1999, 40:1-16.